Cancer Proteomics Group

Prof. Richard Christopherson

Left-right: Dr Larissa Belov, Prof Richard Christopherson, Dr Ben Crossett (SUPRU), Munther Alomari (PhD), Duthika Mallawaaratchy (PhD), Jerry Zhou (PhD),

Kieran Matic (Honours), Yiping Che (PhD), Dr Kim Kaufman, Trisha Almazi (PhD)

Missing: Dr Swetlana Mactier, Erin Sykes (PhD).

Colorectal cancer (CRC)LeukaemiaMelanomaGlioblastoma (GBM)

Cancers we study:

Identification of proteome changes in cancer cells after treatment with a drug such as:

◦ Purine analogues (e.g., fludarabine) ◦ HSP90 inhibitors (e.g., SNX-7081)◦ ER-stress inducers (e.g., thapsigargin)

Understand mechanisms of drug action and resistance, identification of new drug targets

Anti-cancer drugs

DotScan™ CD antibody microarrays◦ Capture live cells and obtain a surface profile

(disease signature, immunophenotype)◦ In collaboration with major NSW hospitals, we

have collected and tested many different clinical samples, including:

Leukaemias Colorectal cancers Metastatic melanoma

◦ To improve disease stratification, prognostication and prediction of response to treatment

Cell surface markers

Stage III melanoma Survival analyses – prognostic biomarkers good versus poor prognosis groups with

identical stage cancers

Glioblastoma multiformeSerial lesions, pre and post chemotherapy, biomarkers for chemo-resistance

Chronic lymphocytic LeukaemiaStable vs progressive disease course

Comprehensive, quantitative clinical proteomics

Clinical samples and cell lines In vitro chemotherapy treatment Flow cytometry Sub-cellular proteome isolation

◦ Cytosol, nucleus, mitochondria and plasma membrane

Mass Spectrometry and gel-based analyses (SUPRU)

Quantitative analysis◦ DIGE, iTRAQ, SRM and

label-free methods

Techniques

Thank you!

Christopherson lab